


Amendments to the Claims

This listing of claims will replace all prior versions, and listings of claims in the above subject application:

Listing of Claims:


1. (original) A compound of Formula I



Formula I

wherein

R is selected from the group consisting of OH, N₃, -OR₁, -O-aryl, -O-heteroaryl, -OSO₂R₂, -NR₃R₄, and



wherein

- (i) R₁ is benzyl or C₂₋₆-acyl;
- (ii) R₂ is selected from the group consisting of phenyl, tolyl, and C₁₋₈-alkyl; and
- (iii) R₃ and R₄ are independently selected from the group consisting of hydrogen, C₃₋₆-cycloalkyl, phenyl, tert-butoxycarbonyl, fluorenyloxycarbonyl, benzyloxycarbonyl, -CO₂-R₅, -CO-R₅, -CO-SR₅, -CS-R₅, P(O)(OR₆)(OR₇), -SO₂-R₈ and C₁₋₆-alkyl optionally substituted with 1 to 3 members independently selected from the group consisting of C₁₋₅-alkoxycarbonyl, OH, cyano, and halogen, wherein

R₅ is selected from the group consisting of hydrogen, C₃₋₆-cycloalkyl, trifluoromethyl, phenyl, benzyl, and C₁₋₆-alkyl optionally substituted with 1 to 3 members

independently selected from the group consisting of C₁₋₅-alkoxycarbonyl, OH, cyano, halogen, and -NR₉R₁₀ in which R₉ and R₁₀ are independently selected from the group consisting of hydrogen, phenyl and C₁₋₄-alkyl;

R₆ and R₇ are independently hydrogen or C₁₋₄-alkyl; and

R₈ is phenyl or C₁₋₄-alkyl;


R₁₁ is selected from the group consisting of hydrogen, alkyl, -OR₁₃, -SR₁₃, amino, -NR₁₃R₁₄, aryl(C₁₋₈)alkyl, and mono-, di-, tri-, or per-halo C₁₋₈-alkyl;

R₁₂ is selected from the group consisting of CN, -COR₁₃, -COOR₁₃, -CO-NR₁₃R₁₄, -SO₂R₁₃, -SO₂-NR₁₃R₁₄, and nitro; and

R₁₃ and R₁₄ are independently selected from the group consisting of hydrogen, alkyl, and aryl, or R₁₃ and R₁₄ taken together with the nitrogen atom to which they are attached form an unsubstituted or substituted pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, or piperazinyl group;

X is 0 to 4 members independently selected from the group consisting of halogen, OH, mercapto, nitro, halo-C₁₋₈-alkyl, C₁₋₈-alkoxy, C₁₋₈-alkylthio, C₁₋₈-alkyl-amino, di(C₁₋₈-alkyl)amino, formyl, carboxy, alkoxycarbonyl, C₁₋₈ alkyl-CO-O-, C₁₋₈ alkyl-CO-NH-, carboxamide, aryl, heteroaryl, CN, amino, C₃₋₆-cycloalkyl, C₁₋₈-alkyl optionally substituted with one or more members selected from the group consisting of F, Cl, OH, C₁₋₈ alkoxy and C₁₋₈ acyloxy; and

Y is a radical of Formula II:



Formula II

wherein

R₁₅, R₁₆, R₁₇, R₁₈, R₁₉, and R₂₀ are each independently selected from the group consisting of hydrogen, CN, nitro, C₁₋₈-alkyl, halo-C₁₋₈-alkyl, formyl, carboxy, alkoxycarbonyl, carboxamide, aryl, and heteroaryl, or R₁₅ and R₁₆ and/or R₁₇ and R₁₈ and/or R₁₉ and R₂₀ together form an oxo group;

the moiety W represents any five- to ten-membered aromatic or heteroaromatic ring, said heteroaromatic ring having 1 to 4 members selected from the group consisting of S, O, and N;

Z is selected from the group consisting of hydrogen, halogen, amino, alkyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, CN, CHO, alkyl-CO-, alkoxy, (C₁₋₈-alkyl)-CONH-, and R₂₁R₂₂N-alkyl- wherein R₂₁ and R₂₂ are independently selected from the group consisting of hydrogen, C₁₋₆-alkyl, benzyl, aryl, and heteroaryl, or R₂₁ and R₂₂ together with the nitrogen to which they are attached form an unsubstituted or substituted pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, or piperazinyl group; and

m is 0 or 1

and the pharmaceutically acceptable salts and esters thereof.


2. (original) The compound of claim 1 wherein X is halogen.

hydrogen, alkyl, aryl, and heteroaryl.

3. (original) The compound of claim 1 wherein Z is selected from the group consisting of hydrogen, alkyl, aryl, and heteroaryl.

4. (original) The compound of claim 1 wherein the moiety W is a fused phenyl ring or a five- or six-membered heteroaromatic ring having 1 to 4 members selected from the group consisting of S, O, and N.

5. (original) The compound of claim 1 wherein Y is selected from the group consisting of




wherein

Z is selected from the group consisting of hydrogen, alkyl, aryl, heteroaryl, alkyl-CO-, and $R_{21}R_{22}N$ -alkyl- wherein R_{21} and R_{22} are independently selected from the group consisting of hydrogen, C_{1-6} -alkyl, benzyl, aryl, and heteroaryl, or R_{21} and R_{22} together with the nitrogen atom to which they are attached form an unsubstituted or substituted pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, or piperazinyl group.


6. (original) The compound of claim 5 wherein X is halogen and Z is selected from the group consisting of hydrogen, alkyl, aryl, and heteroaryl.

7. (original) The compound of claim 1 wherein R is selected from the group consisting of




8. (original) The compound of claim 6 wherein X is halogen and Z is selected from the group consisting of hydrogen, alkyl, aryl, and heteroaryl.


9. (previously presented) A compound of Claim 1 having the formula:




10. (previously presented) A compound of Claim 1 having the formula:




11. (currently amended) A compound of Claim 1 having the formula:




12. (previously presented) A compound of Claim 1 having the formula:




13. (previously presented) A compound of Claim 1 having the formula:




14. (previously presented) A compound of Claim 1 having the formula:




15. (previously presented) A compound of Claim 1 having the formula:



16. (previously presented) A compound of Claim 1 having the formula:



17. (previously presented) A compound of Claim 1 having the formula:



18. (previously presented) A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier.

19 and 20. (cancelled).

21. (previously presented) A method of treating a subject having a condition selected from the group consisting of community-acquired pneumonia, upper and lower respiratory tract infections, skin and soft tissue infections, bone and joint infections and hospital-acquired lung infections, said method comprising the step of administering to the subject a therapeutically effective amount of a compound according to claim 1.

22. (previously presented) The method of Claim 21 wherein said bacterium is selected from the group consisting of *S. aureus*, *S. epidermidis*, *S. pneumoniae*, *S. pyogenes*, *Enterococcus spp.*, *Moraxella catarrhalis* and *H. influenzae*.

23. (previously presented) The method of Claim 21 wherein said bacterium is a Gram-positive coccus.

24. (original) The method of Claim 23 wherein said Gram-positive coccus is drug-resistant.

25 to 28. (canceled).